Vermillion to Raise up to $31.5M in Equity Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion today said that it has inked an equity investment deal with certain investors to purchase up to $31.5 million of the firm's stock.

The Austin, Texas-based molecular diagnostics firm said that Oracle Investment Management, Jack Schuler, Matthew Strobeck, and other investors have agreed to make an initial investment in the company by purchasing 8 million shares of Vermillion common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.